MX2020010301A - Fragmentos de cdnf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. - Google Patents
Fragmentos de cdnf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos.Info
- Publication number
- MX2020010301A MX2020010301A MX2020010301A MX2020010301A MX2020010301A MX 2020010301 A MX2020010301 A MX 2020010301A MX 2020010301 A MX2020010301 A MX 2020010301A MX 2020010301 A MX2020010301 A MX 2020010301A MX 2020010301 A MX2020010301 A MX 2020010301A
- Authority
- MX
- Mexico
- Prior art keywords
- sequence
- fragment
- pharmaceutical compositions
- terminal
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Abstract
La presente invención proporciona una secuencia de un fragmento de CDNF C-terminal, o una secuencia que tiene al menos 80 % de homología o identidad de secuencia con dicha secuencia. El fragmento CDNF C-terminal protege a las neuronas, neuronas motrices y neuronas dopaminérgicas con RE estresado, y el fragmento es capaz de penetrar la membrana celular neuronal y también la barrera hematoencefálica. La presente invención proporciona, además, dicho fragmento y composiciones farmacéuticas que comprenden dicho fragmento para usarse en el tratamiento de enfermedades y trastornos degenerativos que incluyen enfermedades del sistema nervioso central, diabetes y trastornos retinianos. La presente invención también proporciona una secuencia de un fragmento de MANF C-terminal, o una secuencia que tiene al menos 80 % de homología o identidad de secuencia con dicha secuencia, y composiciones farmacéuticas que comprenden dicho fragmento de MANF para usarse en el tratamiento de enfermedades y trastornos degenerativos que incluyen enfermedades del sistema nervioso central, diabetes y trastornos retinianos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20185304 | 2018-03-29 | ||
| PCT/FI2019/050258 WO2019185994A1 (en) | 2018-03-29 | 2019-03-29 | C-terminal cdnf fragments, pharmaceutical compositions comprising same and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010301A true MX2020010301A (es) | 2020-10-20 |
Family
ID=66103015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010301A MX2020010301A (es) | 2018-03-29 | 2019-03-29 | Fragmentos de cdnf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210009645A1 (es) |
| EP (1) | EP3774858A1 (es) |
| JP (2) | JP2021519578A (es) |
| KR (1) | KR20200138798A (es) |
| CN (1) | CN112616315A (es) |
| AU (1) | AU2019244323A1 (es) |
| BR (1) | BR112020019696A2 (es) |
| CA (1) | CA3094236A1 (es) |
| IL (1) | IL277632A (es) |
| MX (1) | MX2020010301A (es) |
| RU (1) | RU2020131433A (es) |
| SG (1) | SG11202009341TA (es) |
| TW (1) | TW202003015A (es) |
| WO (1) | WO2019185994A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202202898D0 (en) * | 2022-03-02 | 2022-04-13 | Babraham Inst | Novel use |
| WO2024112103A1 (ko) * | 2022-11-22 | 2024-05-30 | 경북대학교 산학협력단 | 신경염증성 질환 치료효과를 나타내는 신규 펩타이드 및 이의 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| ATE140966T1 (de) * | 1990-09-25 | 1996-08-15 | Genentech Inc | Neuer neurotropischer faktor |
| DK1373502T3 (da) * | 2001-03-20 | 2011-01-10 | Amarantus Therapeutics Inc | Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf |
| CA2576030A1 (en) * | 2004-08-09 | 2006-02-23 | Alios Biopharma Inc. | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same |
| JP5236488B2 (ja) | 2005-12-14 | 2013-07-17 | ハーモ ファーマ エルテーデー． | 新規な神経栄養因子タンパク質およびその用途 |
| FI20080326A0 (fi) | 2008-04-30 | 2008-04-30 | Licentia Oy | Neurotroofinen tekijä MANF ja sen käytöt |
| ES2594605T3 (es) * | 2011-06-09 | 2016-12-21 | University Of Miami | Factores neurotróficos MANF y CDNF para uso en el tratamiento de trastornos de la retina |
| FI20115870A0 (fi) | 2011-09-05 | 2011-09-05 | Urmas Arumaee | Neuroprotektiiviset soluihin tunkeutuvat peptidit |
| WO2014191630A2 (en) | 2013-05-28 | 2014-12-04 | Helsingin Yliopisto | Non-human animal model encoding a non-functional manf gene |
| WO2015200469A1 (en) * | 2014-06-24 | 2015-12-30 | University Of Massachusetts | Manf as a regulator of immune system function |
| WO2016057579A1 (en) | 2014-10-06 | 2016-04-14 | Amarantus Bioscience Holdings, Inc. | Methods and compositions for treating retinal disorders |
| EP3619227A1 (en) * | 2017-05-04 | 2020-03-11 | Helsingin Yliopisto | C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof |
| CN107149673A (zh) * | 2017-05-18 | 2017-09-12 | 山东大学 | 神经营养因子cdnf在制备缺血性脑血管疾病药物中的应用 |
-
2019
- 2019-03-29 MX MX2020010301A patent/MX2020010301A/es unknown
- 2019-03-29 US US17/043,028 patent/US20210009645A1/en active Pending
- 2019-03-29 WO PCT/FI2019/050258 patent/WO2019185994A1/en active Application Filing
- 2019-03-29 RU RU2020131433A patent/RU2020131433A/ru unknown
- 2019-03-29 TW TW108111334A patent/TW202003015A/zh unknown
- 2019-03-29 AU AU2019244323A patent/AU2019244323A1/en not_active Abandoned
- 2019-03-29 EP EP19717122.6A patent/EP3774858A1/en active Pending
- 2019-03-29 KR KR1020207031336A patent/KR20200138798A/ko unknown
- 2019-03-29 BR BR112020019696-7A patent/BR112020019696A2/pt not_active IP Right Cessation
- 2019-03-29 SG SG11202009341TA patent/SG11202009341TA/en unknown
- 2019-03-29 JP JP2020552209A patent/JP2021519578A/ja active Pending
- 2019-03-29 CA CA3094236A patent/CA3094236A1/en active Pending
- 2019-03-29 CN CN201980036267.7A patent/CN112616315A/zh active Pending
-
2020
- 2020-09-29 IL IL277632A patent/IL277632A/en unknown
-
2024
- 2024-02-02 JP JP2024014651A patent/JP2024056762A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210009645A1 (en) | 2021-01-14 |
| IL277632A (en) | 2020-11-30 |
| EP3774858A1 (en) | 2021-02-17 |
| CA3094236A1 (en) | 2019-10-03 |
| RU2020131433A (ru) | 2022-05-04 |
| KR20200138798A (ko) | 2020-12-10 |
| JP2021519578A (ja) | 2021-08-12 |
| BR112020019696A2 (pt) | 2021-01-05 |
| AU2019244323A1 (en) | 2020-10-08 |
| WO2019185994A1 (en) | 2019-10-03 |
| CN112616315A (zh) | 2021-04-06 |
| JP2024056762A (ja) | 2024-04-23 |
| SG11202009341TA (en) | 2020-10-29 |
| TW202003015A (zh) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019013157A (es) | Fragmentos de cdnf y manf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. | |
| EP4001277A3 (en) | Bicyclic compounds for diagnosis and therapy | |
| MX2020010301A (es) | Fragmentos de cdnf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. | |
| BR112017014332A2 (pt) | métodos de tratamento de doenças retinianas | |
| PH12020500573A1 (en) | 1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indole derivatives for the treatment, alleviation or prevention of disorders associated with tau aggregates like alzheimer`s disease | |
| MX2009012919A (es) | Tratamiento terapeutico para el sindrome metabolico, diabetes tipo 2, obesidad, o prediabetes. | |
| AU2016249140A8 (en) | Anti-PACAP antibodies and uses thereof | |
| BR112022013843A2 (pt) | Método de diferenciação de células neurais e composições relacionadas e métodos de uso | |
| MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
| EP3712264A8 (en) | Cystathionine beta-synthase enzyme for treatment of homocystinuria | |
| MX2017000378A (es) | ANTICUERPOS DE UNION A PROTOFIBRILLAS BETA AMILOIDE (Aß) MEJORADOS. | |
| MX2021000954A (es) | Terapia de aumento mitocondrial con celulas madre enriquecidas con mitocondrias funcionales. | |
| Damasceno et al. | Frutalin reduces acute and neuropathic nociceptive behaviours in rodent models of orofacial pain | |
| MX2021012608A (es) | Nuevas moleculas para terapia y diagnostico. | |
| MX2021012579A (es) | Composiciones farmaceuticas a base de peptidos de colageno y dispositivos y metodos de produccion y uso de los mismos. | |
| Chang et al. | The effect on serotonin and MDA levels in depressed patients with insomnia when far-infrared rays are applied to acupoints | |
| MX2021008081A (es) | Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa. | |
| Bellavite et al. | Homeopathy and placebo | |
| Karia et al. | Tiapride for the treatment of auditory hallucinations in schizophrenia | |
| MX2021009326A (es) | Pridopidina de dosis baja para mal de parkinson y otras enfermedades asociadas con parkinsonismo. | |
| Wedderburn et al. | Hereditary neuropathy with liability to pressure palsy presenting as an acute brachial plexopathy: a lover's palsy | |
| MX2021000324A (es) | Metodo de prevencion o tratamiento para neuropatia periferica o enfermedad acompa?ada por dolor en la que se reconoce la neuropatia periferica o trastorno de astrocitos. | |
| Sanford et al. | IL-17A Has Some Nerve! | |
| Sarı et al. | The Effect of Rehabilitation without Specific Cognitive Rehabilitation on the Improvement of Cognitive Functions in Stroke Patients: Evaluation with Risk Factors | |
| Mieczyslaw | Breathing and its stimulatory responses in parkinsonism: repercussions for physiotherapy |